Jarvis
  • CATEGORIES
    • Equity Market
    • Investing Basics
    • Interesting Read
    • AI for investing
    • Trending Stock Market News: Quick Reads
    • Portfolio Management
    • Newsletter
  • I AM A
    • Beginner
    • Intermediate
  • Home
  • Products
    • Jarvis Portfolio
    • Jarvis Protect
    • Jarvis OneStock
  • FAQs
  • About Us
  • Contact Us
  • Become a Partner
No Result
View All Result
Jarvis
  • CATEGORIES
    • Equity Market
    • Investing Basics
    • Interesting Read
    • AI for investing
    • Trending Stock Market News: Quick Reads
    • Portfolio Management
    • Newsletter
  • I AM A
    • Beginner
    • Intermediate
  • Home
  • Products
    • Jarvis Portfolio
    • Jarvis Protect
    • Jarvis OneStock
  • FAQs
  • About Us
  • Contact Us
  • Become a Partner
No Result
View All Result
Jarvis
No Result
View All Result
Home Newsletter

Tuesday, 18th May 2021

by Sumit Chanda
May 18, 2021
in Newsletter
Reading Time: 3 mins read
A A
0
Share on FacebookShare on Twitter

Bharti Airtel reported net profits of Rs.759 crore for the Mar-21 quarter compared to a net loss of Rs-5,237 crore in the Mar-20 quarter on account of huge asset impairments provided for. Net profits were lower by 11% on a sequential basis. Total revenues from operations were up 12% at Rs.25,747 crore. The ARPU for the quarter were lower at Rs.145 compared to Rs.166 in Dec-20 quarter. Revenues from India business were up 9.6% yoy while revenues from mobile services rose 19% on strong customer additions.

In a setback for India, ONGC Videsh Ltd or OVL lost the Farzad-B gas field in the Persian Gulf which OVL had discovered. Iran awarded the contract for developing the gas field to a local company. NIOC has signed a $1.78 billion deal with Petropars Group of Iran for the development of the Farzad-B Gas Field. The field holds 23 trillion cubic feet of gas reserves. OVL had offered to invest up to $11 billion to develop Farzad-B but Iran had refused to give a commitment. India has already invested a huge $400 million in the block.

India wholesale inflation or WPI inflation came in higher at 10.49% for Apr-21. This was led by a surge in fuel and manufactured product prices. This is the highest WPI inflation in more than 8 years and is a clear indication of the pressure on costs that manufacturers are facing due to supply chain constraints. For Apr-21, wholesale food inflation was at 4.92%, manufacturing inflation at 9.01% and fuel inflation at a huge 21%. This is a contrast to the CPI inflation which moderated to 4.29% in Apr-21 due to the high base effect.

Balkrishna Industries shot up by 9% to touch a life-time high price of Rs.2,062 on 17 May. For the Mar-21 quarter, the company had reported 29% spike in standalone revenues at Rs.1,746 crore on healthy OEM and replacement demand. Even the EBITDA margins had expanded by 254 basis points to 31.9% on a yoy basis. The net profits had grown by 45% at Rs.372 crore. The stock shot up after BKT guided sales volumes of 265,000 MT. BKT has integrated backward by setting up a carbon black plant as a natural cost hedge.

Gland Pharma reported 34% higher net profits at Rs.260 crore for the Mar-21 quarter on the strength of robust sales growth. Total revenues for the Mar-21 quarter came in Rs.888 crore compared to Rs.635 crore in the Mar-20 quarter. For the full FY21, revenues were higher by 32% at Rs.3,463 crore. The vaccine vertical is expected to accelerate Gland Pharma’s long-term strategy of entering into the Biosimilar space. Gland Pharma had listed just a few months back with its Rs.6,000 crore IPO in the Indian IPO markets.

Panacea Biotech filed a suit before Delhi High Court to restrain Sanofi Healthcare India from marketing a fully liquid hexavalent vaccine. Panacea’s contention is that such a move by Sanofi would infringe its patent for its liquid Hexavalent Vaccine, EasySix. Panacea has submitted that Sanofi had been contesting the patent before the Indian Patent Office since 2017. The EasySix vaccine comes in a pre-filled syringe and vaccinates against Diphtheria, Tetanus, Whooping Cough, Hepatitis B, influenza and Inactivated Polio.

Sumit Chanda

Sumit Chanda

Sumit has 18 years of experience in BFSI industry, into devising strategy for various functions, Investments and Managing Asset Portfolios. Specializes in Strategy & implementation in sales & operations, Team management, IT implementation, Affiliations.

Related Posts

Illustration of bullish and bearish market trends with digital bull and bear icons standing on stacked gold coins, promoting 6 multibagger stocks that surged in 2025. "Is your portfolio still in 2022?" – Jarvis AI

These 6 Multibagger Stocks Exploded in 2025 — Is Your Portfolio Still in 2022?

by Sumit Chanda
June 26, 2025
0
5.3k

In 2025, six multibagger stocks delivered explosive returns—while many investors were still stuck with outdated portfolios. Are you missing the...

Jarvis Invest blog - ‘Liquidity or Inflation? RBI Policy June 2025’ reflecting monetary policy focus

Liquidity or Inflation? RBI Policy June 2025

by Sumit Chanda
June 6, 2025
0
8

On June 6, 2025, the Reserve Bank of India took a bold step to revive economic momentum by slashing both...

Gold vs Stocks: Where should indians invest for better returns?

Gold vs Stocks: Where should Indians invest for better returns?

by Sumit Chanda
May 30, 2025
0
5.3k

As the world’s investment landscape shifts, investors often face the dilemma of where to park their funds for optimal returns....

NRI Investment Plan in India

How can NRIs invest Rs 50 lakh in India?

by Sumit Chanda
May 23, 2025
0
5.3k

When it comes to investment in India, Non-resident Indians (NRIs) are always skeptical about where to invest their hard-earned money....

Top 5 best growth stocks in India and sectors to watch in 2025

Top 5 Best Growth Stocks in India & Sectors to Watch in 2025

by Sumit Chanda
May 8, 2025
0
5.4k

You see the market correction in late 2024 and early 2025 was driven by weak economic data, corporate earnings misses,...

Best sectors to invest in 2025

India’s Fastest-Growing & Best sectors to invest in 2025

by Sumit Chanda
April 29, 2025
0
5.6k

In this blog, we are going to delve into the best sectors to invest in 2025 anticipated to experience the...

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Equity Market
  • Investing Basics
  • AI for investing
  • Trending Stock Market News: Quick Reads
  • Interesting Read
  • Financial Planning
  • Portfolio Management
  • Newsletter
Connect with us: customersupport@jarvisinvest.com

© 2023 Jarvis Invest

No Result
View All Result
  • CATEGORIES
    • Equity Market
    • Investing Basics
    • Interesting Read
    • AI for investing
    • Trending Stock Market News: Quick Reads
    • Portfolio Management
    • Newsletter
  • I AM A
    • Beginner
    • Intermediate
  • Home
  • Products
    • Jarvis Portfolio
    • Jarvis Protect
    • Jarvis OneStock
  • FAQs
  • About Us
  • Contact Us
  • Become a Partner

© 2023 Jarvis Invest

Go to mobile version